Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Akerley, Wallace"" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.
Autorzy:
Goldberg ME; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Montesion M; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Young L; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Suh J; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Greenbowe J; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Kennedy M; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Giaccone G; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C., United States of America.
Akerley WL; Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Dowlati A; University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States of America.
Creelan BC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States of America.
Hicks JK; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States of America.
Hesketh PJ; Lahey Health Cancer Institute, Lahey Hospital & Medical Center, Burlington, Massachusetss, United States of America.
Kelly KL; University of California Davis Cancer Center, Sacramento, California, United States of America.
Riess JW; University of California Davis Cancer Center, Sacramento, California, United States of America.
Miller VA; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Stephens PJ; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Frampton GM; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Ali S; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Gregg JP; Department of Pathology and Laboratory Medicine, UC Davis Health, Sacramento, California, United States of America.
Albacker LA; Foundation Medicine Inc., Cambridge, Massachusetts, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Nov 27; Vol. 13 (11), pp. e0208097. Date of Electronic Publication: 2018 Nov 27 (Print Publication: 2018).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
Drug Resistance, Neoplasm/*genetics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Carcinoma, Non-Small-Cell Lung/pathology ; Cohort Studies ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies